Dr. José A. Queizán Hernández

🩸 Segovia se suma a la I Ruta de Maratones de Donación de Sangre en Castilla y León. 📅 25 de marzo 📍 Acueducto 🕘 10:00–13:00 | 15:45–21:15 Con @donasangreCYL para reforzar reservas antes de #SemanaSanta #Sacyl #DonaciónDeSangre #Segovia

En el Área Privada de la web @sehh_es en el Apartado Publicaciones/Guías-Recomendaciones ya tenéis disponible para su descarga la Guía de #Linfomas 2025 del Grupo de Linfomas y Procesos Linfoproliferativos de @SCLHH1 avalada por @sehh_es y el patrocinio de @GileadSciences

📌 27 de marzo | Jornada de Puertas Abiertas en Segovia para MIR, EIR, PIR y FIR. Presentación de la Formación Sanitaria Especializada del área. 🔗 saludcastillayleon.es/CASegovia/es/n… #Sacyl #FSE #FormaciónSanitaria #CastillayLeón #Segovia

🩸17 equipos, 14 ciudades… y un mismo objetivo: poner a prueba el razonamiento clínico en #trombosis 🏁La Batalla Final de #TromboBattle se celebrará en el curso Hemostasia para tod@s 4.0.👉seth.es/ii-curso-seth-… 🙌Gracias a todos los equipos por formar parte de este reto. #SETH #SETHJoven #CasosClínicos #FormaciónSETH #trombosis #hemostasia #hematología #SomosSETH

📢Abiertas inscripciones para el «II Curso SETH Joven Hemostasia para tod@s 4.0». Dirigido a residentes, adjuntos jóvenes, enfermería, farmacia e investigadores predoctorales interesados en trombosis y hemostasia. 📅 19–20 junio |📍Valdepeñas 👉 Más info: seth.es/ii-curso-seth-… Curso coordinado por: 👩‍⚕️Dra. Olga Benítez (@oBenitez6), del @vallhebron 🧑‍⚕️Dr. José María Bastida (@JMBastidaB), del @IBSAL_IIS, @HematoCAUSA 🧑‍⚕️Dr. Bolívar Díaz (@BolivarDiaz_HEM ), del @HUnivVP, @scmHematologia #SETHJoven #SETH #FormaciónSETH #hemostasia #trombosis #hematología @SEHHJoven

📚📚💪🏻📚📚

A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome @BrJHaem onlinelibrary.wiley.com/doi/10.1111/bj…

Revising #IMWG multiple #myeloma response criteria Do you regularly do paired serum & urine electrophoresis/immunofixation assays? Or only serum? . . #hemonc #heme #oncology #cancer

🔎 Evaluación de la fragilidad para no geriatras: guía práctica completa Francesc Formiga @FormigaFrancesc · J. Ángel Pérez Rivera 👉 Lee el artículo completo y aprende a integrar la valoración de fragilidad en tu práctica clínica diaria: cardioteca.com/cardiologia-cl… 🧠 La fragilidad es un síndrome clínico distinto del envejecimiento o la comorbilidad y aumenta el riesgo de eventos adversos, hospitalización y mortalidad. 📊 Escalas como FRAIL, CFS o el fenotipo de Fried permiten identificarla de forma rápida y con impacto real en la toma de decisiones. ❤️ Detectarla modifica objetivos terapéuticos y estrategias en cardiología, medicina interna, nefrología o atención primaria. 🏃‍♂️ El ejercicio multicomponente y la optimización nutricional son las intervenciones con mayor evidencia para revertir la prefra­gilidad.

Prefibrotic myelofibrosis: recent updates in diagnosis, prognostication, and management 2026 journals.sagepub.com/doi/10.1177/20…

Efficacy and Safety of the C5 Inhibitor Crovalimab in Patients With Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta-Analysis onlinelibrary.wiley.com/doi/full/10.11…

Marginal Zone Lymphoma: 2026 Update on Diagnosis and Management - PubMed pubmed.ncbi.nlm.nih.gov/41867085/?utm_…

🧵 Nivo-AVD for classical Hodgkin lymphoma (cHL): latest key studies / pearls 1.🔥 Frontline Nivo-AVD is now one of the biggest practice-changing regimens in advanced-stage cHL. The landmark phase III SWOG S1826 compared N-AVD vs BV-AVD in newly diagnosed stage III/IV cHL and showed a clear PFS advantage for N-AVD. 2.📊 In S1826, with median follow-up around 2.1 years, 2-year PFS was 92% with N-AVD vs 83% with BV-AVD, with HR 0.45 for progression or death. That is the headline number everyone should know. 3.✅ Another major point: immune-related AEs were infrequent with nivolumab, while BV-AVD had more treatment discontinuation. So this was not only an efficacy story, but also a tolerability story. 4.🎯 Radiotherapy use was very low in S1826, which strengthened the appeal of N-AVD as a highly effective systemic platform without frequent consolidative RT. 5.👴 In older adults, N-AVD is especially interesting. Review data summarizing S1826 showed that in patients ≥60 years, 1-year PFS was 93% with N-AVD vs 64% with BV-AVD, with less neuropathy, less discontinuation, and less non-relapse mortality. 6.🧓 A dedicated phase II older-adult trial of frontline N-AVD also looked strong: among response-evaluable patients, with median follow-up of 49 months, 3-year PFS was 79% and 3-year OS was 97%. 7.💉 Toxicity in that older-adult phase II study was still meaningful, so this is not “gentle” therapy: about 50% had grade 3/4 treatment-related AEs, febrile neutropenia 8%, and 10% stopped therapy because of toxicity. Fit selection still matters. 8.🧠 Clinical takeaway: for a fit adult with advanced-stage cHL, especially when trying to avoid BV-related neuropathy and excess discontinuation, N-AVD has become a leading frontline option on the basis of randomized phase III data. 9.⚠️ Important nuance: the strongest evidence is for advanced-stage disease (stage III/IV). Do not automatically extrapolate these results to all early-stage presentations without disease-specific evidence. 10.🧪 Before S1826, the signal came from CheckMate 205 phase II, where nivolumab followed by N-AVD in newly diagnosed advanced-stage cHL showed promising efficacy and safety, helping justify the later phase III trial. 11.📚 So the evidence ladder is: CheckMate 205 ➜ early proof-of-concept SWOG S1826 ➜ randomized phase III practice-changing confirmation Older-adult phase II data ➜ supports feasibility in selected older fit patients. 12.🏁 Bottom line: Nivo-AVD is one of the most important recent advances in frontline advanced cHL, with better PFS than BV-AVD and a favorable toxicity profile, especially regarding neuropathy/discontinuation. In 2026 discussions, this regimen belongs at the center of frontline advanced cHL decision-making. Key studies •SWOG S1826 / NEJM 2024: Nivolumab+AVD vs BV+AVD in newly diagnosed advanced-stage cHL. •CheckMate 205 / JCO 2019: phase II proof-of-concept for frontline N-AVD. •Older-adult phase II / JCO 2025: frontline N-AVD in older adults. #HodgkinLymphoma #cHL #Nivolumab #AVD #HemeOnc #Lymphoma #KFSHRC

Marginal Zone Lymphoma: 2026 Update on Diagnosis and Management onlinelibrary.wiley.com/doi/10.1002/aj… #lymsm

🚨 ¿ "Paneles de Trombofilia" a todos los pacientes con Tromboembolismo Venoso (TEV)? 🛑 Una excelente revisión en Annals of Phlebology nos recuerda por qué el enfoque debe ser rigurosamente selectivo. Aquí te resumo las perlas para tu práctica clínica diaria 🧵👇 @GT_Trombo @CordobaETV @gabi_puchepalao @UsuarezMD @carranzajhonny1 @ricardo_bedon @ResidentesSEMI @ETVgregorio @mmartinasenjo @PabloDemelo doi.org/10.37923/phle.…

#mdpijcm #Editor’s Choice Paper🔍 ✅ Citations 13 A Comprehensive Review of 𝐂𝐚𝐭𝐡𝐞𝐭𝐞𝐫-𝐑𝐞𝐥𝐚𝐭𝐞𝐝 𝐓𝐡𝐫𝐨𝐦𝐛𝐨𝐬𝐢𝐬 🔗mdpi.com/3098364 @MediPharma_MDPI ✍️Marina López-Rubio et al. #upperextremitydeepveinthrombosis; #venousthromboembolism

Saber RCP puede salvar una vida. ❤️‍🩹  Profesionales del Hospital de Segovia enseñan en este vídeo cómo hacerlo bien youtube.com/watch?v=Fusj6e… #Sacyl #RCP #Segovia

Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid Syndrome | New England Journal of Medicine nejm.org/doi/full/10.10…

Nivolumab + AVD approved for advanced stage Hodgkin lymphoma #lymsm

In 1L cHL Stg III or IV, #Nivolumab + AVD is now ✅ @US_FDA approved based off @SWOG 1826 (vs. #Brentuximab + AVD): - mPFS not reached. PFS HR: 0.42 - ⬆️ neuropathy & discontinuation w/ Bv-AVD - Adopted in clinical practice since its presentation. Now SoC #lysm #HemeTwitter